Pharmalive - The Pulse of the Pharmaceutical Industry


Search Criteria: Search In:  
Special Reports Conferences

Browse Categories
Biotech Companies
Brands
DTC Advertising
Healthcare Agencies
Japanese Pharma Companies
Life Sciences Investment
Medical Device Companies
New Drugs
Personnel and Leadership
Pharma Companies
Pipelines
Specialty Pharma Companies
Therapeutic Categories

Featured Report

Price: $345.00
Published: 03/2010
Format: PDF
Total pages: 136

CNS/Neurology Review and Outlook

Introductory rate of $345 expires 3/24/10. Save $70 off the regular rate of $415. Click the sample link below to view the complete table of contents and select pages.

CNS/Neurology represents one of the two-largest therapeutic areas in the industry in terms products sales as well as the number of compounds in clinical development. The latter element is a very significant factor considering that many of the blockbuster medicines from the past decade for CNS and neurology have lost patent protection or are nearing the loss of their market exclusivity. CNS disorders are the most significant disease burden in high-income countries and is expected to substantially grow in other regions, including Asia, as the standard of living increases.


The following information is included in this special report, which details the leading disease/medical-use areas within the central nervous system and neurology categories:
Primary CNS/Neurology areas covered include Alzheimer’s disease, major depression disorder,
schizophrenia, Parkinson’s disease, epilepsy/seizures, migraine, insomnia/sleep disorders, bipolar disorder, and ADHD. For these areas as well as others, various charts and analysis of the current market leaders and anticipated future growth drivers are provided.
Prescription-drug pipeline covering various CNS/Neurology indications, detailing the following for each product:

• Each pipeline products’ chemical or substance composition, intended indication, class of
drug, clinical status, region of development, and the product developer/intended marketer
• Pipeline status details preclinical development, Phase I, Phase I/II, Phase II, Phase II/III, Phase
III, and awaiting approval
• Region of development includes the United States, Europe, and Japan

A directory of CNS/Neurology prescription-drug developers and marketers, includes the following
information for each company:
• Mailing address
• General phone, fax, e-mail, and Website
• Year established

A listing of CNS/Neurology medical-device entries, sorted by device class, includes the following details for each product:
• Product code
• Product description
• Registration number
• Company

A directory of medical-device company entries (includes divisions and subsidiaries) that are
associated with CNS/neurology devices, includes the following information for each company:
• FDA Establishment Registration Number
• Mailing address
• General phone, fax, e-mail, and Website
• Year established


view sample | View TOC | add to cart


Search for a Report

Build Reports On Demand
PharmaLive OnDemand Special Reports allow users to generate custom reports by selecting only the data they need. The report cost is based on the amount of data selected.

Choose a starting point below and click "Create Report". As you move through the selection process, you will be able to create additional filters.

Company Report
Disease/Medical Usage Report
Therapeutic Category Report
Phase of Development Report

Biotech Companies View All
Biotech/Biopharma/Biosimilar Review and Outlook 2010

Mergers & Acquisitions, Partnerships, & Collaborations 2010 - Review and Outlook


Brands View All
Top 500 Prescription Medicines 2009

Combo Report, Drugs in the Pipeline and on the Market


DTC Advertising View All
Report Combo: New Drugs Outlook, Direct-to-Consumer, and Advertising Account Rosters: Healthcare Marketing Communications Agencies

Direct-to-Consumer Advertising: Analysis of DTC Spend by Brand, Company, and Media


Healthcare Agencies View All
Report Combo: New Drugs Outlook, Direct-to-Consumer, and Advertising Account Rosters: Healthcare Marketing Communications Agencies

Account Rosters: Healthcare Marketing Communications Agencies 2009


Japanese Pharma Companies View All
Top 20 Japanese Companies and Their Pipelines 2009

Top Company Combination: Top 50 Pharma, Top 50 Biotech, Top 50 Specialty Companies, and Top 15 Japanese Pharma Companies


Life Sciences Investment View All
Biotech/Biopharma/Biosimilar Review and Outlook 2010

Global Bioscience Private Venture Investment Review: 2Q09 & 1H09 Trend Analysis


Medical Device Companies View All
Mergers & Acquisitions, Partnerships, & Collaborations 2010 - Review and Outlook

Top Companies Review: Business Overview and Outlook Top 50 Pharmaceutical Companies and Their Pipelines, Top 50 Biotechnology Companies and Their Pipelines , and Top 100 Medical Device Companies


New Drugs View All
CNS/Neurology Review and Outlook

Report Combo: New Drugs Outlook, Direct-to-Consumer, and Advertising Account Rosters: Healthcare Marketing Communications Agencies


Personnel and Leadership View All
People on the Move: First-Third Quarters 2009

People on the Move: Third-Quarter 2009


Pharma Companies View All
Biotech/Biopharma/Biosimilar Review and Outlook 2010

Mergers & Acquisitions, Partnerships, & Collaborations 2010 - Review and Outlook


Pipelines View All
CNS/Neurology Review and Outlook

Biotech/Biopharma/Biosimilar Review and Outlook 2010


Specialty Pharma Companies View All
Mergers & Acquisitions, Partnerships, & Collaborations 2010 - Review and Outlook

Top 50 Specialty Companies 2009


Therapeutic Categories View All
CNS/Neurology Review and Outlook

Weight-Management Outlook 2010




©2010 Canon Communications Pharmaceutical Media Group